T. C. Sağlik bakanliği haydarpaşa numune eğİTİm ve araştirma hastanesi İÇ hastaliklari kliNİĞİ

peripheral T-cell subset imbalance as defined by monoclonal 

antibodies. Br J Dermatol 1985; 113: 124-7 

119.   D’Amelio R, Frati C, Fattorossi A, Aiuti F. Peripheral T-cell subset 

imbalance in patients with vitiligo and in their apparently healty 

first-degree relatives. Ann Allergy 1990; 65: 143-5 

120.   Grimes P, Ghoneum M, Stockton T, Payne C, Kelly AP, Alfred L. 

T-cell profiles in vitiligo. J Am Acad Dermatol 1986; 14: 196-201 

121.  Hadler R, Walters C, Jonson B, Chakrabarti SG, Kenny JA Jr. 

Aberrations in T lymphocytes and natural killer cells in vitiligo: a 

flow cytometric study. J Am Acad Dermatol 1986; 14: 733-7 

 

74

122.  Mozzanica N, Frigerio U, Fizni AF, Cattaneo A, Negri M, 

Scaglione F, Fraschini F, Foppa S. T cell subpopulations in vitiligo: 

a chronobiologic study. J Am Acad Dermatol 1990; 22: 223-30 

123.  Cui J, Chen D, Misfedt ML, Swinfand RW, Bystryn JC. 

Antimelanoma antibodies in swine with spontaneously regressing 

melanoma. Pigment Cell Res 1995; 8:60-3 

124.   Lamont S, Smyth J. The Smyth chicken: effect of bursectomy on 

development of a spontaneous postnatal amelanosis. Clin Immunol 

Immunopathol 1981; 21: 407-11 

125.   Bystryn JC. Immune mechanism in vitiligo. Clin Dermatol, 1997; 

15(6): 853-861 

126.   Arıcan Ö, Şaşmaz S, Çetinkaya A. Vitiligo tip ve progresyonunda 

tiroid hormonlarının rolü. Türkderm, 2003; 37: 269-273 

127.   Arıcan Ö. Vitiligo patogenezinde immunitenin rolü.Dermatose 

2006;1:33-37 

128.   Somorin AO, Krahn PM. Vitiligo: A study of 122 cases. Ann Saudi 

Med. 1997; 17(1): 125-127 

129. 

 Kemp EH, Waterman EA, Weetman AP. Immunological 

pathomecanisms in vitiligo. Expert Rev Mol Med, 2001: 1-22 

130.   Gilhar A, Aizen E, Ohana N, Etziozi A: Vitiliginous vs pigmented 

skin response to intradermal administration of interferon gamma. 

Arch Dermatol 1993; 129: 600-604 

131.   Taştan HB, Erol İE, Sayal A, Erbil AH: Vitiligoda eser element ve 

antioksidan düzeyleri. T Klin Dermatol 2003; 13: 141-149 

132.  Schallreuter KU,  Elwary SMA, Gibbons NCJ, Rokos H, Wood 

JM: Activation / deactivition of acetylcholinesterase by H2O2 : 

more evidence for oxidative stres in vitiligo. Biochem Biophys Res 

Common 2004; 315: 502-508 

 

75

133.  Schallreuter KU, Wood JM: Thioredoxin reductase – its role in 

epidermal redox status. J Photochem Photobiol B. 2001; 64: 179-

184 

134.   Roxos H, Beazley WD, Schallreuter KU: Oxidative stres in vitiligo: 

Photooxidation of pterins produces H2O2 and pterin-6-carboxylic 

acid. Biochemical and Biophysical Research Communications 

2002; 292:805-811 

135.   Yu HS: Melanocyte destruction and repigmentation in vitiligo: A 

model for nerve cell damage and regrowth. J Biomed Sci 2002, 9: 

564-573 

136.  Herane MI: Vitiligo and leukoderma in children. Clin Dermatol 

2003; 21: 283-295 

137.   Tu C, Zhao D, Lin X: Levels of neuropeptide-Y in the plasma and 

skin tissue fluids of patients with vitiligo. J Dermatol Sci 2001; 27: 

178-182 

138.   Wu CS, Yu HS, Chang HR, Yu CL, Wu BN: Cutaneous blood flow 

and adrenoreceptor response increase in segmental – type vitiligo 

lesions. J Dermatol Sci 2000; 23: 53-62 

139.  Fargnoli MC, Bolognia JL. Pentachrome vitiligo. J Am Acad 

Dermatol 1995; 33: 853-6 

140.  Ongenae K, Geel NV and Naeyaert JM. Evidence for an 

autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 

90-100 

141.   Koga M, Tango T. Clinical features and course of type A and type 

B vitiligo. Br J Dermatol 1988; 118: 223-8 

142.   Antoniou C, Katsambas A. Guidelines for the treatment of vitiligo. 

Drugs 1992; 43(4). 490-8.  

 

76

143.  Aydemir EH: Çocuklarda vitiligo tedavisi. 1. Ulusal Pediatrik 

Dermatoloji Günleri 2004; 25-29 

144.   Hazneci  E:  Vitiligo  tedavisinde  yenilikler. 19. Ulusal Dermatoloji 

Kongresi 2002; 235-250  

145.   İşçimen A: Akkiz pigmentasyon bozuklukları. Pediatrik 

Dermatoloji. Ed. Tüzün Y, Kotoğyan A, Serdaroğlu S, Çokuğraş H, 

Tüzün B, Mat MC. İstanbul, Nobel Tıp Kitabevleri, 318-326 

146.  Parsad D, Pandhi R, Dogra S, Kumar B: Clinical study of 

repigmentation patterns with different treatment modalities and 

their correlation with speed and stability of repigmentation in 352 

vitiliginous in patches. J Am Acad Dermatol 2004; 50: 63-67 

147.  Hadler RM, Nootheti PK: Ethnic skin disorders overview. J Am 

Acad Dermatol 2003; 48: 143-148 

148.   Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, 

Metzger A: Topical tacrolimus therapy for vitiligo: Therapeutic 

responses and skin Messenger RNA expression of proinflammatory 

cytokines. J Am Dermatol 2004; 51: 52-60 

149.   Hann KS, Im S, Bong HW, Park YK. Treatment of stable vitiligo 

with autologous epidermal grafting and PUVA. J Am Acad 

Dermatol 1995; 32: 943-8 

150.   Suga Y, Butt KI, Takimoto R, Fujioka N, Yamada H, Ogawa H. 

Succesful treatment of vitiligo with PUVA-pigmented autologous 

epidermal grafting. Int J Dermatol 1996; 35: 508-22 

151.   Fabella R, Arrunategui A, Barona MI, Alzate A, Cali DTPH. The 

minigrafting test for vitiligo: Detection of stable lesions for 

melanocyte transplantation. J Am Acad Dermatol 1995; 32: 228-32 

 

77

152.  Volta U, Bardazzi F, Zauli D, et all. Serological screening for 

coeliac disease in vitiligo and alopecia areata. Br J Dermatol 1997 ; 

136 : 801-802.